Veeda Clinical Research Limited Unlisted Share Price Today

Veeda Clinical Research Limited Unlisted Share Price Today

D
DIGITAL WEALTH
Last Updated: November 19, 2026
2.3k views

Veeda Clinical Research Limited — Live Share Info

Latest Price
₹ 450.00
▼ 7.00 (1.53%)
Sector
medical
52-Week Range
₹450.00 - ₹457.00
ISIN
INE01HQ01026

Price History

Date Price (₹)
18 Nov 2026, 04:10 PM 450.00
21 Jul 2026, 11:06 AM 457.00

The Veeda Clinical Research Limited unlisted share price is attracting attention from investors interested in India's clinical research and pharmaceutical services industry. The company operates as a Contract Research Organization (CRO), providing clinical research, drug development and related services to pharmaceutical and biotechnology companies.

Established in 2004, Veeda Clinical Research Limited has expanded its business capabilities across different stages of clinical development. Its operations include early-phase and late-phase clinical trials, bioequivalence studies and preclinical research services.

The company's revenue growth, acquisition-led expansion and proposed IPO are some of the factors investors consider while evaluating its unlisted shares.

In this article, we cover the latest indicative share price, company profile, financial performance, valuation, IPO status and investment risks associated with Veeda Clinical Research Limited.

Veeda Clinical Research Limited Unlisted Share Price

The indicative unlisted share price of Veeda Clinical Research Limited is ₹450 per share, as displayed on Digital Wealth's price tracker as of 18 November 2026.

Unlisted shares do not trade on NSE or BSE. Their prices are generally based on dealer quotations and private market transactions. Therefore, the actual buying or selling price may differ depending on demand, available quantity and transaction terms.

Veeda Clinical Research Share Price – Key Details


Note: The ₹450 price is Digital Wealth's indicative quotation, not an exchange-traded price. The implied market capitalisation is calculated using approximately 6.99 crore outstanding shares and the indicative share price. Market data may change without notice.

About Veeda Clinical Research Limited

Veeda Clinical Research Limited was incorporated on 23 April 2004 and is headquartered in Ahmedabad, Gujarat.

The company operates as an independent Contract Research Organization (CRO), supporting pharmaceutical and biotechnology companies with research services required during the development and evaluation of medicines.

Its business covers multiple stages of drug development, from early research to clinical trials and specialised testing.

Over the years, Veeda has expanded its capabilities through business development and acquisitions. Its acquisition of Heads, a global clinical research organisation specialising in haematology and oncology trials, has strengthened its presence in late-phase clinical research.

The company has also expanded its preclinical research capabilities through Bioneeds India Private Limited.

Key Business Areas of Veeda Clinical Research

1. Early-Phase Clinical Research

Early-phase research involves evaluating the safety, tolerability and pharmacokinetic properties of drug candidates before they progress into later stages of clinical development.

2. Late-Phase Clinical Trials

Late-phase clinical trials help pharmaceutical companies evaluate the effectiveness and safety of medicines in larger patient populations. These studies are important before regulatory approval and commercialisation.

3. Bioequivalence Studies

Bioequivalence studies compare generic medicines with reference products to determine whether they demonstrate comparable absorption and availability in the body.

4. Preclinical Research

Preclinical research involves laboratory and animal studies that help evaluate the safety and characteristics of drug candidates before human clinical trials.

5. Pharmaceutical Research Services

Veeda provides specialised research support to pharmaceutical and biotechnology companies across different stages of drug development.

Veeda Clinical Research Limited Financial Performance

Financial performance is an important consideration when evaluating an unlisted company.

Veeda has reported significant revenue growth, supported partly by acquisitions and expansion of its research capabilities. However, higher depreciation, finance costs and acquisition-related expenses have affected its reported profitability.

The following table presents selected consolidated financial figures.

Consolidated Financial Performance

Source: Company's consolidated financial statements and available credit-rating disclosures. Figures are rounded.

FY2025–26 Financial Performance

Available secondary-market financial data indicates the following figures for FY2025–26:

Note: These are secondary-market reported figures. Verify the audited FY2025–26 financial statements before treating them as final reported results. The reporting basis should also be checked before comparing them with previous-year figures.

Revenue Growth

Veeda's consolidated revenue increased from approximately ₹388.78 crore in FY2024 to ₹609.73 crore in FY2025.

This growth reflects the expansion of its business operations and the contribution of acquired businesses.

Available FY2026 market data indicates revenue of approximately ₹715.5 crore, suggesting further growth in the company's operations.

Profitability and Operating Performance

Despite the improvement in revenue, profitability remains an important area to monitor.

The company reported a consolidated net loss of approximately ₹66.81 crore in FY2025. Higher depreciation, finance costs and certain non-recurring expenses contributed to the reported loss.

According to CareEdge Ratings, the company's FY2025 PBILDT margin was approximately 27.5%, compared with 21.3% in FY2024.

Available FY2026 financial data indicates an improvement in EBITDA and a reduction in the reported net loss. Investors should examine operating cash flow, debt obligations, finance costs and audited profitability before making investment decisions.

Veeda Clinical Research Limited Share Price and Valuation

At an indicative price of ₹450 per share, Veeda Clinical Research Limited has an implied market capitalisation of approximately ₹3,144 crore, based on around 6.99 crore outstanding shares.

However, the market capitalisation alone does not establish whether the company's shares are fairly valued.

Investors should also consider its revenue growth, operating margins, outstanding borrowings, net worth and ability to generate sustainable profits.

Important Valuation Factors

Revenue Growth: Consistent growth in clinical research revenue can support the company's long-term business prospects.

Operating Margins: Improving operating margins may indicate better cost management and business efficiency.

Net Profitability: The company's ability to move towards sustainable positive earnings remains an important valuation factor.

Debt Position: Borrowings and finance costs should be evaluated because they can affect future earnings and cash flow.

IPO Prospects: Regulatory developments and progress towards the proposed public offering may influence investor expectations.

Market Demand: Unlisted share prices depend on private market demand and available supply, which can result in differences between dealer quotations.

Veeda Clinical Research Limited IPO Status

Veeda Clinical Research Limited has taken steps towards a public listing.

The company filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) in connection with its proposed initial public offering.

The IPO proposal includes a fresh issue of ₹185 crore and an offer for sale of up to 1.3 crore equity shares by existing shareholders, according to the reported DRHP details.

The proposed fresh issue proceeds were intended for capital expenditure, investment in Bioneeds India, repayment of certain borrowings, business expansion and general corporate purposes.

The proposed offering is subject to applicable regulatory requirements and market conditions.

Filing a DRHP does not guarantee that an IPO will take place on a particular date. Investors should refer to the latest SEBI disclosures and company announcements for updates.

Until the shares are listed on a recognised stock exchange, Veeda's shares remain part of the unlisted market.

Factors That May Influence Veeda Clinical Research Share Price

Several business and market factors can influence the valuation of Veeda Clinical Research Limited.

1. Growth in the Clinical Research Industry

The pharmaceutical and biotechnology industries require clinical research services to support drug development. Growing demand for clinical trials and outsourced research may create opportunities for established CRO companies.

2. Expansion of Research Capabilities

Expansion across early-phase, late-phase and preclinical research can help Veeda serve a wider range of pharmaceutical and biotechnology clients.

3. International Business Operations

Veeda has an international customer base, with exports contributing approximately 63% of its standalone revenue in FY2025, according to CareEdge Ratings.

A diversified customer base may support business opportunities, although client concentration and international regulatory requirements remain important considerations.

4. Acquisition Integration

The company's acquisition of Heads and expansion of its stake in Bioneeds have broadened its service capabilities.

The ability to achieve expected operational efficiencies and synergies from these acquisitions will be important for future financial performance.

5. Improvement in Profitability

Revenue growth alone does not determine business performance. Sustainable profits, cash flow generation and effective debt management will be important factors for investors.

6. IPO Developments

Any progress regarding the proposed IPO may influence investor sentiment in the unlisted market. However, investors should not assume that a particular listing timeline or valuation is guaranteed.

Risks of Investing in Veeda Clinical Research Unlisted Shares

Before investing in Veeda Clinical Research Limited unlisted shares, investors should understand the associated risks.

1. Limited Liquidity

Unlike listed shares, unlisted shares do not have an active exchange-based trading market. Finding a buyer and completing a sale may take time.

2. Financial Performance

The company reported a consolidated net loss of approximately ₹66.81 crore in FY2025. Although available FY2026 data indicates a reduction in losses, sustainable profitability remains important.

3. Valuation Risk

Indicative unlisted market prices may not reflect the company's eventual listing valuation or fair market value.

4. IPO Uncertainty

A DRHP filing does not guarantee an IPO or a particular listing date. Regulatory developments and market conditions can affect the proposed offering.

5. Acquisition Integration Risk

The company needs to successfully integrate its acquired businesses and achieve expected operating efficiencies.

6. Regulatory and Business Risks

Clinical research companies operate under strict regulatory requirements. Changes in clinical trial regulations, research costs and client requirements may affect business operations.

7. Price Fluctuations

Dealer quotations can vary depending on available inventory, transaction size and market demand.

How to Buy Veeda Clinical Research Limited Unlisted Shares?

Investors interested in purchasing Veeda Clinical Research Limited unlisted shares can explore transactions through established unlisted share intermediaries.

The general process involves:

  1. Check the latest indicative share price and available quantity.
  2. Compare quotations and transaction terms from different intermediaries.
  3. Verify the intermediary and complete the required KYC formalities.
  4. Review payment instructions and share transfer documentation.
  5. Confirm the transfer and verify the credit of shares in your demat account.

Before completing a transaction, independently verify the ISIN, seller ownership, depository details and applicable tax implications.

Frequently Asked Questions (FAQs)

1. What is the Veeda Clinical Research Limited unlisted share price?

The indicative share price displayed by Digital Wealth is ₹450 per share as of 18 November 2026. Actual transaction prices may differ depending on dealer quotations, market demand and share availability.

2. Is Veeda Clinical Research Limited listed on NSE or BSE?

No. Veeda Clinical Research Limited is currently an unlisted company. Its shares are not available for regular trading on NSE or BSE.

3. What is the ISIN of Veeda Clinical Research Limited?

The ISIN of Veeda Clinical Research Limited is INE01HQ01026.

4. What is the face value of Veeda Clinical Research shares?

The face value of Veeda Clinical Research Limited equity shares is ₹2 per share.

5. Has Veeda Clinical Research Limited filed its DRHP?

Yes. The company has filed a Draft Red Herring Prospectus in connection with its proposed initial public offering. Investors should check the latest regulatory disclosures for its current status.

6. What is the business of Veeda Clinical Research Limited?

Veeda operates as a Contract Research Organization (CRO), providing clinical trials, bioequivalence studies, preclinical research and other pharmaceutical research services.

7. Is Veeda Clinical Research Limited profitable?

The company reported a consolidated net loss of approximately ₹66.81 crore in FY2025. Available secondary-market financial data indicates a loss of approximately ₹14 crore in FY2026. Investors should review the latest audited financial statements for confirmation.

8. What is the market capitalisation of Veeda Clinical Research Limited?

At an indicative share price of ₹450 and approximately 6.99 crore outstanding shares, its implied market capitalisation is approximately ₹3,144 crore.

9. What are the risks of investing in Veeda Clinical Research unlisted shares?

The key risks include limited liquidity, valuation fluctuations, financial performance, acquisition integration, regulatory requirements and uncertainty surrounding the proposed IPO.

10. Can I sell Veeda Clinical Research unlisted shares?

Yes. Unlisted shares can generally be sold through private off-market transactions, subject to applicable regulations, transfer requirements and the availability of buyers. The process may take longer than selling listed shares.

Conclusion

Veeda Clinical Research Limited operates in India's clinical research and pharmaceutical services industry, with capabilities across early-phase, late-phase and preclinical research.

Its revenue growth, international business operations and acquisition-led expansion are important aspects of its business profile. At the same time, investors should carefully evaluate its reported losses, debt position, operating cash flow and ability to achieve sustainable profitability.

At an indicative price of ₹450 per share on Digital Wealth as of 18 November 2026, investors should assess the company's financial performance and valuation before considering an investment.

The proposed IPO is another development worth monitoring, but its timing and outcome should not be assumed.


Disclaimer: This article is for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell unlisted shares. Unlisted investments involve liquidity, market and valuation risks. Share prices are indicative and may change without notice. Investors should conduct independent research and consult a qualified financial advisor before making investment decisions.